Healthcare - Biotechnology - NASDAQ - US
$ 0.6142
-4.72 %
$ 3 M
Market Cap
-0.05
P/E
CASH FLOW STATEMENT
-9.85 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
0
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Virpax Pharmaceuticals, Inc.
| Net Income | -15.2 M |
| Depreciation & Amortization | 12.9 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 545 K |
| Change in Working Capital | 4.79 M |
| Others | -595 M |
| Free Cash Flow | -9.85 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (15.2) | (21.7) | (12.1) | (4.3) | (3.3) | (2.6) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 0.5 | 0.7 | 1.0 | 1.5 | 0.7 | 0.4 |
| Other Operating Activities | 0 | 0.7 | 61.8 K | 0.2 | 0.6 | 15 K |
| Change in Working Capital | 4.8 | 3.1 | (3.4) | 1.3 | 0.9 | 0.4 |
| Cash From Operations | (9.9) | (17.8) | (14.5) | (1.4) | (1.1) | (1.8) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Items | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | (1.5) | 72.1 K | 0.5 | 0.6 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (5.2) | 50.9 K | 0.6 | 0 |
| Cash From Financing Activities | 0 | 0 | 51.3 | 1.4 | 1.1 | 1.7 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (9.9) | (17.8) | 36.8 | 13.3 K | 6.83 K | (0.1) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (9.9) | (17.8) | (14.5) | (1.4) | (1.1) | (1.8) |